e99435bbb170d.LCnl5KWP0pV3V5CBd3q5JFBNjxYvcjCRruWZaeJG0co.c3GptPDhgNRDLqDCGyzqZhkoy0l3R2rU-6yqC5sSuptDSoTXldijwRZm8w
07-02 Endologix Publishes 36-Month Results from the Detour2 Clinical Trial Evaluating the Detour System CI
05-19 Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc. CI
05-07 Endologix LLC Announces Appointment of Steve Deitsch to Board of Directors CI
09/07/25 Endologix Announces That Scott Huennekens Joins Board of Directors CI
20/03/25 Endologix Announces 1000 Patients Treated with the Detour? System CI
03/03/25 Endologix LLC Appoints Andrew Davis as Chief Commercial Officer CI
07/01/25 Endologix LLC Announces Chief Executive Officer Changes CI
07/01/25 Endologix LLC Announces Executive Changes CI
06/11/24 Endologix LLC Announces 36-Month Results of Detour2 Study At 2024 Viva Late-Breaking Clinical Trial Session CI
18/06/24 Endologix LLC Appoints Graham Phillips as Chief Operating Officer CI
13/05/24 Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery CI
05/03/24 Endologix LLC Appoints Mike Mathias as Chief Commercial Officer CI
25/01/24 Endologix LLC Announces That Art Taylor Joins Board of Directors CI
09/01/24 Endologix LLC Appoints Scott Ward Joins Board of Directors CI
09/01/24 Endologix LLC Announces Appointment of Scott Ward as Board of Directors CI
27/12/23 Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System CI
02/11/23 Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session CI
07/09/23 Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System CI
24/08/23 Endologix LLC Appoints Lucas Buchanan to its Board of Directors CI
18/07/23 Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease CI
15/06/23 Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting CI
08/06/23 Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad CI
23/05/23 Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial CI
11/11/22 Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session CI
03/11/22 Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial CI

Become a member to access more news

New member
No results match your criteria